期刊文献+

微管结合蛋白Tau磷酸化位点突变体的构建及鉴定 被引量:1

Construction and Detection of Tau Phosphorylation Site Mutation
下载PDF
导出
摘要 目的:构建带有Myc标签的Thr-213、Thr-235、Ser-404磷酸化位点突变为Ala的Tau蛋白真核表达质粒,并在真核细胞中表达Myc-Tau3m蛋白。方法:利用重组PCR方法得到Thr-213、Thr-235、Ser-404磷酸化位点突变为Ala的编码序列,将其插入经Bam HⅠ和KpnⅠ酶切的p XJ40-Myc表达载体,在人293T细胞中转入空载体和重组质粒,利用Western印迹检测其表达及功能。结果:测序和酶切结果证实Myc-Tau3m真核表达质粒构建成功,转染293T细胞后获得表达,表达产物可促进微管的乙酰化。结论:构建了Thr-213、Thr-235、Ser-404磷酸化位点突变的Myc-Tau3m真核表达载体,为进一步研究Tau蛋白磷酸化的生理机能奠定了基础。 Objective: To construct the human Tau(T231A, S235A, S404A) mutation and detect its function in regulating microtubules acetylation. Methods: The human Tau(T231A, 5235A, S404A) mutation was obtained by recombinant PCR and cloned into pXJ40-Myc vector. The recombinant plasmid was transfected into 293T cells, and the expression of Myc-Tau3m and mierotubules acetylation was detected by Western blot. Results: Myc- Tau3m eukaryotie expression vector labeled with Mye tag was successfully constructed. The inserted fragment was confirmed by sequencing. Myc-Tau3m was expressed in 293T cells and enhanced the acetylation of microtubules. Conclusion: The eukaryotic expression vector of Myc-Tau3m was successfully constructed and expressed in 293T cells.
出处 《生物技术通讯》 CAS 2016年第1期44-47,共4页 Letters in Biotechnology
基金 国家自然科学基金(81372161 31470773 81272231)
关键词 微管结合蛋白Tau 突变体 磷酸化 真核表达 Tau, mutation phosphorylation eukaryotic expression
  • 相关文献

参考文献10

  • 1Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-asso- ciatedprotein Tau. A component of Alzheimer paired helical filaments[J]. J Biol Chem, 1986,261(13):6084-6089.
  • 2Alafuzoff I, Arzberger T, A1-Sarraj S, et al. Staging of neurofi- brillary pathology in Alzheimer's disease: a study of the Brain- Net Europe Consortium[J]. J Brain Pathol, 2008,18(4):484-496.
  • 3Mandelkow E, von Bergen M, Biernat J, et al. Structural prin- ciples of Tau and the paired helical filaments of Alzheimer's disease[J]. J Brain Pathol, 2007,17:83-90.
  • 4Hertze J, Minthon L, Zetterberg H, et al. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical fol- low-up study of 4.7 years[J]. J Alzheimers Dis, 2010,21: 1119-1128.
  • 5Galasko D, Clark C, Chang L, et al. Assessment of CSF lev- els of Tau protein in mildly demented patients with Alzheim- er's disease[J]. J Neurology, 1997,48:632-635.
  • 6Smet-Nocca C, Broncel M, Wieruszeski J M, et al. Identifica- tion of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation[J]. J Mol Biosyst, 2011,7: 1420-1429.
  • 7Liu S J, Zhang A H, Li H L, et al. Overactivation of glyco- gensynthase kinase-3 by inhibition of phosphoinositol-3 ki- nase andprotein kinase C leads to hyperphosphorylation of Tau andimpairment of spatial memory[J]. J Neurochem, 2003, 87(6):1333-1344.
  • 8Zhang Y J, Xu Y F, Liu Y H, et al. Nitric oxide induces Tan hyperphosphorylation via glycogen synthase kinase-3beta activation[J]. J FEBS Lett, 2005,579(27):6230-6236.
  • 9Ren Q G, Liao X M, Wang Z F, et al. The involvement of glycogen synthase kinase-3 and protein phosphatase-2A in lactacystininduced Tau accumulation[J]. J FEBS Lett, 2006, 580(10):2503-2511.
  • 10Li X H, Lv B L, Xie J Z, et al. AGEs induce Alzheimer- like Tan pathology and memory deficit via RAGE-mediated GSK-3 activation[J]. J Neurobiol Aging, 2012,33(7):1400-1410.

同被引文献36

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部